Thymosin Alpha 1
Support the system that protects you.
Vial content, not a dose.
Thymosin Alpha 1 is a 28-amino-acid peptide, acetylated at one end, derived from a larger precursor protein called prothymosin alpha. It was first isolated from calf thymus in 1977 — the thymus being the gland where T-cells learn what belongs to the body and what does not. Rather than pushing the immune system broadly, it is studied as a modulator: a peptide involved in how immune cells mature, communicate, and calibrate the scale of their response.
Thymosin Alpha 1 is not a foreign stimulant. It comes from prothymosin alpha, a protein the body makes itself, and the research describes it as recalibrating — restoring balance between arms of the immune response rather than pushing one harder. That distinction is the premise the rest of this catalog runs on: a signal returned to the conversation, not a new order given to it.
How the signal travels.
Most of what is known about how this peptide works begins at a single receptor on dendritic cells — the cells that decide what the immune system pays attention to, and how strongly.
Thymosin Alpha 1 signals through TLR9 on dendritic cells, an innate-immune sensor that determines whether and how these cells escalate a response to what they encounter.
Downstream, the signal travels the MyD88 adaptor to IRF7 and onward to IDO, the intracellular relay that translates receptor engagement into a coordinated, regulated output rather than a blunt one.
That signaling is described as enhancing dendritic-cell maturation and natural killer cell cytotoxicity — two of the immune system's earliest responders, sharpened rather than overdriven.
Further along, research describes effects on T-cell maturation and on Th1/Th2 balance — the relative weighting of two arms of the adaptive response, adjusted rather than amplified.
What it's used to support.
Most relevant for women 35 and older paying attention to immune resilience alongside the hormonal and metabolic shifts of this stage — slower recovery from ordinary illness, or a sense that the body's defenses respond differently than they once did. It suits those who want a mechanism they can follow, evaluated with a practitioner rather than assumed.
The figures above are the amount of lyophilized peptide in the vial — they are not a dose. Your protocol, timing, and duration are set one-to-one with a licensed practitioner based on your history and goals.
The specifics, if you want them.
Technical specifications
Where the research stands
Thymosin Alpha 1 carries one of the deeper human research records in this catalog: decades of controlled trials, including a Phase 3 program in chronic hepatitis B, plus study in hepatitis C combination regimens, sepsis, and immune support during cancer care. Beyond those settings the evidence thins — broad immune-resilience use is not established to the same standard.
Storage & handling
Before you start.
It is supplied here as a 20 mg vial — that figure is the content of the vial, not a dose. We do not publish a protocol: route, amount, and frequency are determined case by case with a licensed practitioner, not published generically, based on your health history and what else is already part of your care.
We do not attach a timeline to it. Immune signaling is not something you feel changing hour to hour, and response depends on your baseline, on the rest of your protocol, and on what prompted the conversation in the first place. That judgment belongs to whoever is reading your labs, not to us.
Yes. Thymosin Alpha 1 acts on immune regulation, which means it has to be considered against your full history — anything you already take, and anything already under management. A licensed practitioner reviews that picture and confirms whether this belongs in your plan before anything begins.
The research frames it as modulation rather than stimulation. Through TLR9 signaling on dendritic cells it is described as recalibrating T-cell maturation and the Th1/Th2 balance — adjusting the proportion of a response rather than raising its volume. That distinction matters, and it is why this peptide is discussed in terms of balance rather than boost.
It is derived from prothymosin alpha, a protein the body produces, and was first isolated from thymus tissue in 1977. The version used in peptide therapy is synthesized to that same 28-amino-acid, acetylated structure. It is not a novel molecule invented in a lab — it is a copy of a signal already in the body's repertoire.
Every Inner Peptides formula is independently tested before it ships, with a Certificate of Analysis available on request. Learn more about our testing standard.
